博济医药（300404）8月25日主力资金净流入1847.71万元

Core Insights - Boji Pharmaceutical (300404) closed at 11.76 yuan on August 25, 2025, with a 3.43% increase and a turnover rate of 16.99% [1] - The company reported a total revenue of 139 million yuan for Q1 2025, a year-on-year decrease of 17.06%, and a net profit attributable to shareholders of 3.90 million yuan, down 76.38% year-on-year [1] Financial Performance - Total revenue for Q1 2025: 139 million yuan, down 17.06% year-on-year [1] - Net profit for Q1 2025: 3.90 million yuan, down 76.38% year-on-year [1] - Non-recurring net profit: 1.70 million yuan, down 88.28% year-on-year [1] - Current ratio: 1.935, Quick ratio: 1.418, Debt-to-asset ratio: 31.99% [1] Market Activity - Main capital inflow: 18.48 million yuan, accounting for 3.32% of transaction volume [1] - Large orders net inflow: 19.49 million yuan, accounting for 3.5% of transaction volume [1] - Small orders net outflow: 23.88 million yuan, accounting for 4.29% of transaction volume [1] Company Background - Boji Pharmaceutical was established in 2002 and is located in Guangzhou, focusing on research and experimental development [2] - The company has invested in 39 enterprises and participated in 113 bidding projects [2] - Intellectual property includes 49 trademarks and 47 patents, along with 44 administrative licenses [2]